Table 2.
Clinical outcomes in the overall population and according to the presence or absence of myocardial injury during the index hospitalization for COVID-19.
| Characteristics | Overall Population (n = 701) |
Presence of Myocardial Injury (n = 75) |
Absence of Myocardial Injury (n = 626) |
p Value |
|---|---|---|---|---|
| All-cause mortality [n, (%)] | 54 (7.7) | 16 (21.3) | 38 (6.1) | <0.001 |
| MACCE [n, (%)] | 47 (6.7) | 19 (25.3) | 28 (4.5) | <0.001 |
| CV death [n, (%)] | 19 (2.7) | 10 (13.3) | 9 (1.4) | <0.001 |
| IHD [n, (%)] | 11 (1.6) | 5 (6.7) | 6 (1.0) | <0.001 |
| Stroke/TIA [n, (%)] | 12 (1.7) | 1 (1.3) | 11 (1.8) | 0.926 |
| Hospitalization for HF [n, (%)] | 18 (2.6) | 7 (9.3) | 11 (1.8) | <0.001 |
| Arrhythmias [n, (%)] | 38 (5.4) | 7 (9.3) | 31 (5.0) | 0.034 |
| New onset AF [n, (%)] | 33 (4.7) | 6 (8.0) | 27 (4.3) | 0.072 |
| Ventricular arrhythmias [n, (%)] | 5 (0.7) | 1 (1.3) | 4 (0.6) | 0.174 |
| Inflammatory heart disease [n, (%)] | 13 (1.9) | 6 (8.0) | 7 (1.1) | <0.001 |
| Pericarditis [n, (%)] | 10 (1.4) | 4 (5.3) | 6 (1.0) | 0.001 |
| Myocarditis [n, (%)] | 4 (0.6) | 2 (2.7) | 2 (0.3) | 0.004 |
| Thrombotic disorders [n, (%)] | 15 (2.1) | 1 (1.3) | 14 (2.2) | 0.681 |
| Pulmonary embolism [n, (%)] | 6 (0.9) | 0 (0.0) | 6 (1.0) | 0.415 |
| Deep vein thrombosis [n, (%)] | 10 (1.4) | 1 (1.3) | 9 (1.4) | 0.997 |
| Superficial vein thrombosis [n, (%)] | 1 (0.1) | 0 (0.0) | 1 (0.2) | 0.736 |
| Follow-up time [days, median (IQR)] | 270 [165; 380] | 201 [130; 357] | 272 [168; 381.25] | 0.006 |
Legend to table: COVID-19—Coronavirus Disease-2019; MACCE—major adverse cardiovascular and cerebrovascular events; CV—cardiovascular; IHD—ischemic heart disease; TIA—transient ischemic attack; HF—heart failure; AF—atrial fibrillation; IQR—interquartile range.